{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 40,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights clinical efficacy in Phase 1a and 1b trials for various cancers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/30",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.65,
        "y": 0.2
      },
      "kind": "image",
      "text": "Molecular structure diagram showing CD137, Urelumab, and CTX-471 binding sites.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44ae8004-b752-4416-8578-8005116c04db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "CTX-471: next generation CD137 agonist\nFully human, IgG4, optimized affinity for agonistic antibody\nUnique epitope: non-ligand blocking",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47a91c47-31c7-4096-8372-c405422e95d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.03,
        "y": 0.4
      },
      "kind": "list",
      "text": "Phase 1 Study Update\nMonotherapy in post checkpoint inhibitor patients\nMonotherapy Phase 1a multiple ascending dose study completed\nNear PR in a patient with mucosal melanoma\nProlonged stable disease in two patients with NSCLC\nMTD defined by immune thrombocytopenia\nMonotherapy Phase 1b dose expansion study nearing completion\n4 PRs observed so far: small cell lung cancer, mucosal melanoma, metastatic melanoma, and mesothelioma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df0c2611-42c1-48ba-a862-2bd94feaa4c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.68,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "*Eskiocak, et al. JCI Insight. 2020;5(5):e133647",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4667924-9e8d-4f65-accc-24ed8f170d64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "CTX-471: Potential Best-in-Class CD137 Agonist",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "570ec9f3-59b4-4529-8bc7-80ec6f55a200",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}